Shandong Xinhua Pharmaceutical announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd.'s azithromycin dry suspension passed the generic drug quality and efficacy consistency evaluation. In February 2024, Xinda Pharmaceutical submitted consistency evaluation registration materials to the National Medical Products Administration Drug Evaluation Center and obtained acceptance, and received the approval notice in December 2024.
新华制药:阿奇霉素干混悬剂通过仿制药一致性评价
Shandong Xinhua Pharmaceutical: Azithromycin dry suspension passed the generic drug consistency evaluation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.